153 related articles for article (PubMed ID: 31249992)
1. Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects.
De Cristofaro R; Sacco M; Lancellotti S; Berruti F; Garagiola I; Valsecchi C; Basso M; Di Stasio E; Peyvandi F
TH Open; 2019 Apr; 3(2):e123-e131. PubMed ID: 31249992
[No Abstract] [Full Text] [Related]
2. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.
Healey JF; Parker ET; Lollar P
J Thromb Haemost; 2018 Feb; 16(2):303-315. PubMed ID: 29197156
[TBL] [Abstract][Full Text] [Related]
3. Predictive immunogenicity of Refacto AF.
Delignat S; Repessé Y; Gilardin L; Dimitrov JD; Lone YC; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2014 Jul; 20(4):486-92. PubMed ID: 24372710
[TBL] [Abstract][Full Text] [Related]
4. The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro.
Ofosu FA; Tse H; Naqvi A; Bhakta H; Song Y
Haemophilia; 2012 Nov; 18(6):917-25. PubMed ID: 22672786
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
Musso R
Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
[TBL] [Abstract][Full Text] [Related]
6. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.
Anzengruber J; Lubich C; Prenninger T; Gringeri A; Scheiflinger F; Reipert BM; Malisauskas M
J Thromb Haemost; 2018 Jun; 16(6):1176-1181. PubMed ID: 29665242
[TBL] [Abstract][Full Text] [Related]
9. Management of bleeding disorders: basic science.
Ofosu FA; Santagostino E; Grancha S; Marco P
Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
[TBL] [Abstract][Full Text] [Related]
10. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
11. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
Berntorp E
Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
[TBL] [Abstract][Full Text] [Related]
14. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
[TBL] [Abstract][Full Text] [Related]
15. Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates.
Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12686. PubMed ID: 35356665
[TBL] [Abstract][Full Text] [Related]
16. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
17. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
18. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
19. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
20. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]